Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan - Quiz - MDSpire

Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan

  • By

  • Mizuki Haraguchi

  • Hisashi Yamamoto

  • Otoya Watanabe

  • Takashi Sakoh

  • Keiko Ishida

  • Sho Ogura

  • Masayo Katoh-Morishima

  • Yuki Taya

  • Aya Nishida

  • Daisuke Kaji

  • Shinsuke Takagi

  • Go Yamamoto

  • Naoyuki Uchida

  • Hideki Araoka

  • June 17, 2023

  • 0 min

Share

Original Source(s)

Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan

  • by Mizuki Haraguchi, Hisashi Yamamoto, Otoya Watanabe, Takashi Sakoh, Keiko Ishida, Sho Ogura, Masayo Katoh-Morishima, Yuki Taya, Aya Nishida, Daisuke Kaji, Shinsuke Takagi, Go Yamamoto, Naoyuki Uchida, Hideki Araoka

  • June 17, 2023

Related Content

MIS-C: Diagnosis, Management, and Outcomes

Rare COVID Vaccine Clotting Linked to Adenoviral Protein 

Antibody proteomics and immunogenetics identify adenoviral protein VII as the trigger of PF4-targeting antibodies 

  • April 21, 2026

  • 2 min
Models of autoantibody mediated diseases: actively nearing the human gold standard